| Treatment of rna virus infection with a cytidine Y Saunthararajah, BK Jha, X Gu US Patent App. 18/552,615, 2024 | | 2024 |
| Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof Y Saunthararajah, J DeSimone, LAU Henry, S Vadivelu US Patent App. 18/459,683, 2024 | | 2024 |
| Oncotherapy resistance explained by Darwinian and Lamarckian models Y Saunthararajah Journal of Clinical Investigation 134 (8), e179788, 2024 | | 2024 |
| Pharmacologic Therapies in Beta Hemoglobinopathies: Fetal Globin Gene Induction in the First Molecular Diseases KHM Kuo, AD Faller, D Lavelle, Y Saunthararajah, SP Perrine Medical Research Archives 12 (3), 2024 | | 2024 |
| Compositions comprising decitabine and tetrahydrouridine and uses thereof J DeSimone, Y Saunthararajah US Patent App. 18/239,460, 2024 | | 2024 |
| Treatment of rna virus infection with a cytidine deaminase inhibitor Y Saunthararajah, X Gu | | 2024 |
| Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies PG Woost, BM William, BW Cooper, M Ueda Oshima, F Otegbeye, ... Cytometry Part B: Clinical Cytometry 106 (1), 11-24, 2024 | 1 | 2024 |
| Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results … M Goldfinger, A Epstein, I Mantzaris, A Shastri, K Gritsman, N Kornblum, ... Blood 142, 4258, 2023 | | 2023 |
| RUNX1 Germline Mutations of Autosomal-Dominant Familial Platelet Disorder Are More Common Than Expected in Adult Myeloid Leukemias Indicating Highly Variable Penetrance C Haddad, Y Kubota, C Bravo-Perez, C Gurnari, L Guarnera, O Ogbue, ... Blood 142, 2736, 2023 | | 2023 |
| Compositions comprising decitabine and tetrahydrouridine and uses thereof J DeSimone, Y Saunthararajah US Patent 11,786,543, 2023 | | 2023 |
| Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof Y Saunthararajah, J DeSimone, LAU Henry, S Vadivelu US Patent 11,779,591, 2023 | | 2023 |
| MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, R Zhao, G Choudhary, ... Clinical Lymphoma Myeloma and Leukemia 23, S355, 2023 | | 2023 |
| POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, R Zhao, G Choudhary, ... Clinical Lymphoma Myeloma and Leukemia 23, S181, 2023 | | 2023 |
| Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine H Lau, PG Woost, U Friedrich, WHO Clausen, JW Jacobberger, ... European Journal of Haematology 111 (3), 345-355, 2023 | 2 | 2023 |
| Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy S Biswas, K Kang, KP Ng, T Radivoyevitch, K Schalper, H Zhang, ... Cell reports 42 (8), 2023 | 2 | 2023 |
| Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF V Ibanez, K Vaitkus, X Zhang, J Ramasamy, AE Rivers, Y Saunthararajah, ... Blood Advances 7 (15), 3891-3902, 2023 | 6 | 2023 |
| P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA K Fedorov, E Feldman, Y Saunthararajah, A Shastri, N Kornblum, A Sica, ... HemaSphere 7 (S3), e90768e2, 2023 | | 2023 |
| A metabolically optimized, noncytotoxic low-dose weekly decitabine/venetoclax in MDS and AML D Levitz, Y Saunthararajah, K Fedorov, LC Shapiro, I Mantzaris, A Shastri, ... Clinical Cancer Research 29 (15), 2774-2780, 2023 | 5 | 2023 |
| DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway D Karan, M Singh, S Dubey, PJ Van Veldhuizen, Y Saunthararajah Cancers 15 (10), 2763, 2023 | 2 | 2023 |
| 5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE Y Saunthararajah, PG Woost, U Friedrich, WHO Clausen, ... HemaSphere 7 (S1), 16, 2023 | | 2023 |
